Welcome to our dedicated page for Tenaya Therapeutics news (Ticker: TNYA), a resource for investors and traders seeking the latest updates and insights on Tenaya Therapeutics stock.
Tenaya Therapeutics develops therapies intended to address underlying causes of heart disease, with a clinical-stage pipeline led by TN-201 and TN-401 gene therapies. TN-201 is an AAV9-based gene therapy for MYBPC3-associated hypertrophic cardiomyopathy, and TN-401 targets PKP2-associated arrhythmogenic right ventricular cardiomyopathy.
Company news commonly covers clinical data from the MyPEAK-1 and RIDGE-1 studies, financial results, cardiovascular research collaborations, and preclinical work supporting TN-301, a highly selective HDAC6 inhibitor studied for heart failure and related cardio/muscular disease. Updates also reference Tenaya’s target identification and validation capabilities, including iPSC-derived cardiomyocytes, engineered heart tissue models and in vivo disease models.
Tenaya Therapeutics (NASDAQ: TNYA) reported Q2 2024 financial results and provided a business update. Key highlights include:
1. Received Rare Pediatric Disease Designation for TN-201 for MYBPC3-associated HCM
2. UK clearance to initiate clinical testing of TN-401 for PKP2-Associated ARVC
3. Established $45 Million Credit Facility with Silicon Valley Bank
4. Anticipates sharing interim Phase 1b results for TN-201 in H2 2024
5. Plans to begin dosing patients in TN-401 RIDGE-1 trial in Q4 2024
6. Q2 2024 financial results: R&D expenses $22.6M, G&A expenses $8.2M, net loss $29.4M ($0.34 per share)
7. Cash position of $99.3M as of June 30, 2024, expected to fund operations into H2 2025
Tenaya Therapeutics, a clinical-stage biotech focused on heart disease therapies, announced significant leadership updates. Kathy Ivey, Ph.D., is promoted to Senior Vice President of Research, taking charge of all non-clinical research and discovery. Timothy Hoey, Ph.D., steps down as Chief Scientific Officer but will continue as an advisor and join the Scientific Advisory Board (SAB). Barry J. Byrne, M.D., Ph.D., a pediatric cardiologist and genetic therapy expert, is appointed to the SAB. Additionally, Jin-Long Chen, Ph.D., resigns from the Board of Directors to pursue other commitments.
Ivey, instrumental in Tenaya's formation, has led projects like TN-201 and TN-401 gene therapies. Byrne's addition brings expertise in genetic therapies for cardiomyopathies affecting young people. These leadership changes aim to strengthen Tenaya's mission to develop curative therapies for heart disease.
On June 18, 2024, Tenaya Therapeutics, a clinical-stage biotechnology company focused on developing therapies for heart disease, announced its participation in the TD Cowen Genetic Medicines & RNA Summit. The company's CEO, Faraz Ali, will present on June 21, 2024, at 11:20 am ET. The live presentation will be webcast, accessible from the Investors section of Tenaya's website, with a replay available for 30 days post-conference.
Tenaya Therapeutics (NASDAQ: TNYA) reported its Q1 2024 financial results, revealing a net loss of $32.2 million, or $0.40 per share. The company raised $47 million in net proceeds, extending its cash runway to the second half of 2025. R&D expenses were $25.1 million, slightly down from $25.6 million in Q1 2023, while G&A expenses remained flat at $8.7 million.
Tenaya continues to focus on its gene therapy programs, expecting initial data from its TN-201 Phase 1b trial in H2 2024 and has activated clinical sites for its TN-401 Phase 1b trial. In line with cost containment measures, Tenaya plans to cut its workforce by 22%.
Recent academic publications highlight the potential of their TN-301 for heart failure and TN-401 for ARVC. With strategic hires and ongoing innovations, Tenaya aims to meet critical milestones in its clinical programs.
Tenaya Therapeutics, Inc. will showcase its advances in capsid engineering, gene editing, and manufacturing at the ASGCT 27th Annual Meeting. The company will present seven abstracts highlighting its capabilities in genetic medicines for heart disease. Tenaya's pipeline includes clinical-stage gene therapies for cardiomyopathies and research on gene therapy, gene editing, and cardiac cell regeneration using AAV as a delivery vehicle. The presentations will cover capsid engineering insights, gene editing efforts, and manufacturing process optimizations to improve AAV-based gene therapies' safety and efficacy.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.